Intestinal mononuclear phagocytes as prognostic biomarker for crohn's disease
US-2024425923-A1 · Dec 26, 2024 · US
US9605313B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9605313-B2 |
| Application number | US-201313782901-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 1, 2013 |
| Priority date | Mar 2, 2012 |
| Publication date | Mar 28, 2017 |
| Grant date | Mar 28, 2017 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Technology provided herein relates in part to methods, processes and apparatuses for non-invasive assessment of genetic variations.
Opening claim text (preview).
What is claimed is: 1. A method for enriching fetal nucleic acid in sample nucleic acid that includes fetal nucleic acid and maternal nucleic acid, comprising: (a) obtaining cell-free circulating sample nucleic acid from a biological sample from a pregnant female; and (b) separating some or substantially all of the fetal nucleic acid from the maternal nucleic acid by contacting the sample nucleic acid with a H1M-specific antibody or H1FOO-specific antibody, thereby generating a separation product enriched for fetal nucleic acid relative to fetal nucleic acid in the sample nucleic acid. 2. The method of claim 1 , wherein the sample nucleic acid is from blood plasma. 3. The method of claim 1 , wherein obtaining the sample nucleic acid comprises subjecting the biological sample to an in vitro process that isolates the sample nucleic acid from other sample components. 4. The method of claim 3 , wherein the in vitro process comprises centrifugation. 5. The method of claim 1 , wherein the separation product comprises about 50% or greater fetal nucleic acid. 6. The method of claim 1 , further comprising sequencing the nucleic acid in the separation product using a nucleotide sequencing process, thereby generating nucleotide sequence reads. 7. The method of claim 6 , further comprising detecting the presence or absence of a genetic variation according to the nucleotide sequence reads wherein the genetic variation is a chromosome aneuploidy. 8. The method of claim 7 , wherein the chromosome aneuploidy is a chromosome 21 aneuploidy.
against material from animals or humans · CPC title
for diseases caused by alterations of genetic material · CPC title
Nucleic acid analysis using immunogens (immunoassay G01N33/53) · CPC title
Single or double stranded nucleic acid binding proteins · CPC title
involving nucleic acids · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.